Decellularised tendon-based mitral annuloplasty ring reduced regurgitation to 15.5%±3.0%, comparable to commercial rings, and maintained effective MVA around 2.27 cm².
Does a decellularised tendon-based annuloplasty ring reduce regurgitation comparably to commercial rings in an in vitro degenerative mitral regurgitation model?
A novel decellularised tendon-based mitral annuloplasty ring demonstrated comparable regurgitation suppression and effective mitral valve area to commercial rings in an in vitro degenerative mitral regurgitation model.
Absolute Event Rate: 0% vs 0%
Abstract OBJECTIVES Conventional annuloplasty rings used in mitral valve repair (MVr) are made of metal or synthetic polymers, which may increase infection risk. This study aimed to develop a mitral annuloplasty ring using decellularised tissue and evaluate its ability to suppress regurgitation in a degenerative mitral regurgitation (DMR) model. METHODS A 4 mm diameter annuloplasty ring was created using decellularized bovine tendon. Porcine mitral valve complexes (including the annulus, leaflets, chordae tendineae, and papillary muscles) were obtained from a slaughterhouse. The annulus was enlarged by 4 mm, and the two chordae tendineae of the posterior leaflet (P2) were severed. The DMR model, integrated into a pulsatile flow simulator, was repaired using a commercial—Physio II, Colvin-Galloway (CG) Future, Tailor band, and a decellularised tendon-based ring. Regurgitation control and effective mitral valve area (MVA) were compared (n = 6 for each group). RESULTS The regurgitation rate of the DMR model was 52.3 ± 3.4%, consistent with severe MR. Post-MVr with each ring, the regurgitation rates were 14.9 ± 3.1% (Physio II), 14.5 ± 1.1% (CG Future), 16.4 ± 1.7% (Tailor band), and 15.5 ± 3.0% (decellularised tendon-based biological ring). All of these rates were significantly reduced, with no significant differences among them. Effective MVA was comparable across groups: 2.46 ± 0.28 cm2 (Physio II), 2.33 ± 0.54 cm2 (CG Future), 2.28 ± 0.12 cm2 (Tailor band), and 2.27 ± 0.53 cm2 (decellularised tendon-based biological ring). CONCLUSIONS The decellularised tendon-based annuloplasty ring demonstrated functional performance comparable to that of current mitral annuloplasty devices.
Katayama et al. (Tue,) reported a other. Decellularised tendon-based mitral annuloplasty ring reduced regurgitation to 15.5%±3.0%, comparable to commercial rings, and maintained effective MVA around 2.27 cm².